CN106029070A - 艾日布林和mTOR抑制剂作为治疗癌症的联合疗法的用途 - Google Patents

艾日布林和mTOR抑制剂作为治疗癌症的联合疗法的用途 Download PDF

Info

Publication number
CN106029070A
CN106029070A CN201580011593.4A CN201580011593A CN106029070A CN 106029070 A CN106029070 A CN 106029070A CN 201580011593 A CN201580011593 A CN 201580011593A CN 106029070 A CN106029070 A CN 106029070A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
cancer
eribulin
everolimus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580011593.4A
Other languages
English (en)
Chinese (zh)
Inventor
B.A.利特尔菲尔德
Y.富纳哈施
T.尤纳卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Publication of CN106029070A publication Critical patent/CN106029070A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580011593.4A 2014-03-03 2015-03-02 艾日布林和mTOR抑制剂作为治疗癌症的联合疗法的用途 Pending CN106029070A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461947398P 2014-03-03 2014-03-03
US61/947398 2014-03-03
PCT/US2015/018335 WO2015134399A1 (en) 2014-03-03 2015-03-02 Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
CN106029070A true CN106029070A (zh) 2016-10-12

Family

ID=54055761

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580011593.4A Pending CN106029070A (zh) 2014-03-03 2015-03-02 艾日布林和mTOR抑制剂作为治疗癌症的联合疗法的用途

Country Status (11)

Country Link
US (1) US20170071903A1 (enExample)
EP (1) EP3113775A4 (enExample)
JP (1) JP2017507151A (enExample)
KR (1) KR20160135230A (enExample)
CN (1) CN106029070A (enExample)
AU (1) AU2015225436A1 (enExample)
CA (1) CA2940983A1 (enExample)
IL (1) IL247586A0 (enExample)
RU (1) RU2016136504A (enExample)
SG (1) SG11201607298QA (enExample)
WO (1) WO2015134399A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113271977A (zh) * 2018-11-09 2021-08-17 G1治疗公司 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE046436T2 (hu) 2004-06-03 2020-02-28 Eisai R&D Man Co Ltd Köztitermékek halikondrin B elõállításához
MA33127B1 (fr) 2009-03-30 2012-03-01 Eisai R&D Man Co Ltd Composition liposomique
JP6404242B2 (ja) 2013-06-26 2018-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用
US12029724B2 (en) 2016-04-28 2024-07-09 Eisai R&D Management Co., Ltd. Method for inhibiting tumor growth
WO2019097073A1 (en) 2017-11-20 2019-05-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596197A (zh) * 2009-08-27 2012-07-18 生物学特性有限公司 用于治疗增生性疾病的联合疗法
WO2012119077A1 (en) * 2011-03-02 2012-09-07 Morphotek Inc. Co -administration of eribulin and farletuzumab for the treatment of breast cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2447891C2 (ru) * 2006-04-05 2012-04-20 Новартис Аг Комбинации терапевтических средств, предназначенные для лечения рака
WO2013152034A1 (en) * 2012-04-02 2013-10-10 Merrimack Pharmaceuticals, Inc. Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596197A (zh) * 2009-08-27 2012-07-18 生物学特性有限公司 用于治疗增生性疾病的联合疗法
WO2012119077A1 (en) * 2011-03-02 2012-09-07 Morphotek Inc. Co -administration of eribulin and farletuzumab for the treatment of breast cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113271977A (zh) * 2018-11-09 2021-08-17 G1治疗公司 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案

Also Published As

Publication number Publication date
RU2016136504A3 (enExample) 2018-10-25
RU2016136504A (ru) 2018-04-03
AU2015225436A1 (en) 2016-09-08
EP3113775A4 (en) 2017-08-23
JP2017507151A (ja) 2017-03-16
CA2940983A1 (en) 2015-09-11
IL247586A0 (en) 2016-11-30
US20170071903A1 (en) 2017-03-16
EP3113775A1 (en) 2017-01-11
SG11201607298QA (en) 2016-09-29
WO2015134399A1 (en) 2015-09-11
KR20160135230A (ko) 2016-11-25

Similar Documents

Publication Publication Date Title
CN106029070A (zh) 艾日布林和mTOR抑制剂作为治疗癌症的联合疗法的用途
KR102676705B1 (ko) 암을 치료하는 방법
US11266654B2 (en) Apilimod compositions and methods for using same
RU2739992C2 (ru) Композиции апилимода и способы их применения в лечении колоректального рака
Mihailidou et al. Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models
US20140024653A1 (en) Compositions and methods for treating cancer using pi3k inhibitor and mek inhibitor
EP2570127A1 (en) Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
JP2020528052A (ja) がん治療におけるエリブリン及びサイクリン依存的キナーゼ阻害剤の使用
Lee et al. IPI-493, a potent, orally bioavailable HSP90 inhibitor of the ansamycin class
Zhong et al. 152 POSTER Prevention and treatment of bortezomib-induced peripheral neuropathy by the Hsp90 inhibitor tanespimycin (KOS-953) in the rat
US20220071982A1 (en) Methods and uses for treating cancer
OA16446A (en) Compositions comprising a PI3K inhibitor and a MEK inhibitor and their use for treating cancer.
NZ722491B2 (en) Apilimod compositions and methods for using same
HK1242965B (en) Apilimod for use in the treatment of colorectal cancer
HK1242204B (en) Apilimod for use in the treatment of melanoma
OA16757A (en) Compositions and methods for treating cancer using P13K beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors.
HK1226329B (en) Apilimod compositions for treating non-hodgkin's b cell lymphoma
HK1193754A (en) Combinations of akt and mek inhibitor compounds, and methods of use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20161012

RJ01 Rejection of invention patent application after publication